Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 09 April, 2020

QIAGEN N.V.

QIAGEN announces preliminary Q1 2020 results

DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Preliminary Results/Quarterly / Interim Statement
QIAGEN N.V.: QIAGEN announces preliminary Q1 2020 results

09-Apr-2020 / 18:29 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc Announcement according to Art. 17 Market Abuse Regulation



QIAGEN announces preliminary Q1 2020 results

Venlo, The Netherlands, April 9, 2020 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces preliminary sales and adjusted earnings per share results for the first quarter of 2020.

Net sales rose approximately 9% at constant exchange rates (CER) compared to the outlook for the first quarter announced on February 4, 2020, for approximately 2-3% CER growth. Sales results reflected very significant demand for solutions used in COVID-19 pandemic testing against weaker customer demand trends in other product areas. Adjusted earnings per share (EPS) are expected to be about $0.34-0.35 CER based on preliminary results compared to the outlook for the first quarter for approximately $0.28-0.29 CER.

Based on actual exchange rates as of March 31, 2020, QIAGEN expects currency movements against the U.S. dollar (reporting currency) to have an adverse impact on results for the first quarter of 2020 of about two percentage points on net sales at actual rates, and resulting in an adverse impact of up to $0.01 per share on adjusted EPS.

Further information will be provided when QIAGEN reports full results for the first quarter of 2020 in early May 2020.

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

ISIN: NL0012169213

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

Contacts QIAGEN N.V.:

Corporate Communications

John Gilardi, Tel: +49 2103 29 11711; [email protected]


Forward Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products (including anticipated sales of its QuantiFERON latent TB Test, its portfolio of next generation sequencing solutions and QIAstat-Dx), adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of digital PCR products, a new version of its QuantiFERON-TB test, QuantiFERON-TB Access, the QIAstat-Dx panel for respiratory conditions and a CE-IVD marked panel for meningitis), placements of QIAsymphony modular PCR instruments, improvements in operating and financial leverage, currency movements against the U.S. dollar, and plans for investment in its portfolio and share repurchase commitments, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; as well as the possibility that expected benefits related to recent or pending acquisitions, including the pending acquisition by Thermo Fisher Scientific Inc., may not materialize as expected; and the other factors discussed under the heading "Risk Factors" contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

 


09-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: [email protected]
Internet: www.qiagen.com
ISIN: NL0012169213
WKN: A2DKCH
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX
EQS News ID: 1019975

 
End of Announcement DGAP News Service

1019975 09-Apr-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1019975&application_name=news&site_id=financialexpress

a d v e r t i s e m e n t